全文获取类型
收费全文 | 6299篇 |
免费 | 324篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 139篇 |
妇产科学 | 129篇 |
基础医学 | 845篇 |
口腔科学 | 118篇 |
临床医学 | 570篇 |
内科学 | 1718篇 |
皮肤病学 | 192篇 |
神经病学 | 486篇 |
特种医学 | 115篇 |
外科学 | 619篇 |
综合类 | 19篇 |
预防医学 | 675篇 |
眼科学 | 60篇 |
药学 | 419篇 |
中国医学 | 20篇 |
肿瘤学 | 502篇 |
出版年
2023年 | 48篇 |
2022年 | 92篇 |
2021年 | 237篇 |
2020年 | 107篇 |
2019年 | 227篇 |
2018年 | 270篇 |
2017年 | 127篇 |
2016年 | 151篇 |
2015年 | 156篇 |
2014年 | 271篇 |
2013年 | 337篇 |
2012年 | 529篇 |
2011年 | 610篇 |
2010年 | 302篇 |
2009年 | 275篇 |
2008年 | 411篇 |
2007年 | 414篇 |
2006年 | 379篇 |
2005年 | 427篇 |
2004年 | 306篇 |
2003年 | 335篇 |
2002年 | 249篇 |
2001年 | 33篇 |
2000年 | 28篇 |
1999年 | 38篇 |
1998年 | 49篇 |
1997年 | 52篇 |
1996年 | 26篇 |
1995年 | 23篇 |
1994年 | 18篇 |
1993年 | 17篇 |
1992年 | 10篇 |
1991年 | 8篇 |
1990年 | 11篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 9篇 |
1986年 | 3篇 |
1984年 | 3篇 |
1983年 | 8篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1976年 | 3篇 |
1974年 | 4篇 |
1973年 | 4篇 |
1971年 | 3篇 |
1966年 | 2篇 |
1964年 | 3篇 |
1963年 | 3篇 |
排序方式: 共有6660条查询结果,搜索用时 15 毫秒
991.
992.
Belmatoug N Burlina A Giraldo P Hendriksz CJ Kuter DJ Mengel E Pastores GM 《Journal of inherited metabolic disease》2011,34(5):991-1001
Miglustat (Zavesca®) is approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease (GD1) for whom enzyme replacement therapy is unsuitable, and for the treatment of progressive neurological manifestations in adult and paediatric patients with Niemann-Pick disease type C (NP-C). Gastrointestinal disturbances such as diarrhoea, flatulence and abdominal pain/discomfort have consistently been reported as the most frequent adverse events associated with miglustat during clinical trials and in real-world clinical practice settings. These adverse events are generally mild or moderate in severity, occurring mostly during the initial weeks of therapy. The mechanism underlying these gastrointestinal disturbances is the inhibition by miglustat of intestinal disaccharidase enzymes (mainly sucrase and maltase), leading to sub-optimal hydrolysis of carbohydrates and subsequent osmotic diarrhoea and altered colonic fermentation. Transient decreases in body weight, which are often observed during initial miglustat therapy, are considered likely due to gastrointestinal carbohydrate malabsorption and associated negative caloric balance. While most cases of diarrhoea resolve spontaneously during continued miglustat therapy, diarrhoea also responds well to anti-propulsive medications such as loperamide. Dietary modifications such as reduced consumption of dietary sucrose, maltose and lactose have been shown to improve the gastrointestinal tolerability of miglustat and reduce the magnitude of any changes in body weight, particularly if initiated at or before the start of therapy. Miglustat dose escalation at treatment initiation may also reduce gastrointestinal disturbances. This article discusses these aspects in detail, and provides practical recommendations on how to optimize the gastrointestinal tolerability of miglustat. 相似文献
993.
Infective endocarditis (IE) is a difficult and complex disease. In recent years epidemiology and microbiology have changed. In developed countries IE is now affecting older patients and patients with no previously known valve disease. Prosthetic IE (prosthetic valve endocarditis [PVE]) and endocarditis in patients with pacemakers and other devices (cardiac device related infective endocarditis [CDRIE]) are becoming more frequent. The number of Staphylococcus aureus IE is increasing related to the number of endocarditis that occurs because of health care associated procedures, especially in diabetics or patients on chronic hemodialysis. The change in the underlying population and the increase in the number of cases caused by very virulent organism explain why the disease still carries a poor prognosis and a high mortality. The variety of clinical manifestations and complications, as well as the serious prognosis, makes it mandatory that IE patients need to be treated in experienced hospitals with a collaborative approach between different specialists, involving cardiologists, infectious disease specialists, microbiologists, surgeons, and frequently others, including neurologists and radiologists. Only an early diagnosis followed by risk stratification and a prompt institution of the correct antibiotic treatment as well as an appropriate and timed surgical indication may improve mortality figures. The recent European Guidelines try to provide clear and simple recommendations, obtained by expert consensus after thorough review of the available literature to all specialists involved in clinical decision-making of this difficult and changing disease. 相似文献
994.
995.
Hanna N Jiménez de Bagüés MP Ouahrani-Bettache S El Yakhlifi Z Köhler S Occhialini A 《The Journal of infectious diseases》2011,203(8):1129-1135
In murine infections, Brucella microti exhibits an atypical and highly pathogenic behavior resulting in a mortality of 82%. In this study, the possible involvement of the virB type IV secretion system, a key virulence factor of Brucella sp., in this lethal phenotype was investigated. As previously described for B. suis, expression of the virB operon of B. microti was induced in acid minimal medium, partially mimicking intracellular environment. Early neutralization of cellular compartments abolished intracellular replication of B. microti, showing that acidity of the Brucella-containing vacuole is an essential trigger. A ΔvirB mutant of B. microti exhibited strong attenuation in murine and human macrophages in vitro. Interestingly, infection with this mutant was not lethal in Balb/c mice and lacked the typical intrasplenic peak at 3 days post-infection, hence demonstrating that lethality of B. microti in murine infection absolutely requires a functional virB operon. 相似文献
996.
Zarzuelo MJ Jiménez R Galindo P Sánchez M Nieto A Romero M Quintela AM López-Sepúlveda R Gómez-Guzmán M Bailón E Rodríguez-Gómez I Zarzuelo A Gálvez J Tamargo J Pérez-Vizcaíno F Duarte J 《Hypertension》2011,58(4):733-743
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor β/δ (PPARβ) has been shown to improve insulin resistance and plasma high-density lipoprotein levels, but nothing is known about its effects in genetic hypertension. We studied whether the PPARβ agonist GW0742 might exert antihypertensive effects in spontaneously hypertensive rats (SHRs). The rats were divided into 4 groups, Wistar Kyoto rat-control, Wistar Kyoto rat-treated (GW0742, 5 mg · kg(-1) · day(-1) by oral gavage), SHR-control, and SHR-treated, and followed for 5 weeks. GW0742 induced a progressive reduction in systolic arterial blood pressure and heart rate in SHRs and reduced the mesenteric arterial remodeling, the increased aortic vasoconstriction to angiotensin II, and the endothelial dysfunction characteristic of SHRs. These effects were accompanied by a significant increase in endothelial NO synthase activity attributed to upregulated endothelial NO synthase and downregulated caveolin 1 protein expression. Moreover, GW0742 inhibited vascular superoxide production, downregulated p22(phox) and p47(phox) proteins, decreased both basal and angiotensin II-stimulated NADPH oxidase activity, inhibited extracellular-regulated kinase 1/2 activation, and reduced the expression of the proinflammatory and proatherogenic genes, interleukin 1β, interleukin 6, or intercellular adhesion molecule 1. None of these effects were observed in Wistar Kyoto rats. PPARβ activation, both in vitro and in vivo, increased the expression of the regulators of G protein-coupled signaling proteins RGS4 and RGS5, which negatively modulated the vascular actions of angiotensin II. PPARβ activation exerted antihypertensive effects, restored the vascular structure and function, and reduced the oxidative, proinflammatory, and proatherogenic status of SHRs. We propose PPARβ as a new therapeutic target in hypertension. 相似文献
997.
998.
Benítez Cantero JM Angel Rey JM Rodríguez Perálvarez M Ayllón Terán MD Jurado García J Soto Escribano P Hervás Molina AJ Poyato González A González Galilea A 《Gastroenterologia y hepatologia》2011,34(7):460-463
Eosinophilic esophagitis is an underdiagnosed disease that should be suspected in all patients with dysphagia and food impaction. Although these are the leading symptoms, the clinical and endoscopic spectrum is highly varied. Clinicians should be aware of the risk of endoscopy-related complications in this disorder. Precautions should be maximized in endoscopic examinations to avoid iatrogenic damage. We describe the case of a young patient with esophageal stricture and dysphagia who suffered a perforation following a biopsy. 相似文献
999.
1000.
Bueno-Carrazco J Castro-Leyva V García-Gomez F Solís-Paredes M Ramon-Gallegos E Cruz-Orea A Eguía-Aguilar P Arenas-Huertero F 《Child's nervous system》2012,28(10):1723-1730